Illumina (ILMN) is attracting significant attention within the investment community. The company seems to be delivering mixed financial results with Q3 2024 Earnings posting an EPS of
$4.03, beating the estimated figure. This alongside an earnings top in Q3 and strong momentum status has drawn investor interest, as demonstrated by the increased positions of numerous entities such as
AIA Group Ltd,
Asset Management One Co. Ltd,
National Pension Service, and
Impax Asset Management Group plc. Conversely, entities such as
Carmel Capital Partners LLC and
Kornitzer Capital Management Inc. KS have reduced their stake while
Amalgamated Bank and
Van ECK Associates Corp sold shares.
Further, Illumina has recognized a decrease in revenue in Q3 2024. The company also announced the acquisition of
Fluent BioSciences to enhance single-cell analysis and discovery and launched
DRAGEN v4.3. Analysts continue to adjust price targets and Illumina is expected to beat further earnings estimates. Some uncertainty revolves around the company's lowered 2024 sales views and underperformance compared to competitors.
Illumina ILMN News Analytics from Wed, 28 Feb 2024 08:00:00 GMT to Sat, 09 Nov 2024 14:49:45 GMT -
Rating 2
- Innovation 5
- Information 8
- Rumor -2
